Previous research demonstrated a high occurrence of HER2 amplification in left-sided CRC patients, and that HER2-positive CRCs are mutually exclusive with mutations in KRAS, NRAS, and BRAF oncogenic drivers [18, 19]. This evidence concerns the gene ERBB2 and colorectal carcinoma.